Cardiff Oncology (CRDF) Earnings Date & Reports

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

CRDF is expected to report earnings to fall 12.45% to -19 cents per share on May 01

Cardiff Oncology CRDF Stock Earnings Reports

Q1'25

Est.

$-0.19

Q4'24

Beat

by $0.03

Q3'24

Beat

by $0.02

Q2'24

Missed

by $0.01

Q1'24

Beat

by $0.03

The last earnings report on February 27 showed earnings per share of -21 cents, beating the estimate of -25 cents. With 1.44M shares outstanding, the current market capitalization sits at 202.90M.

View a ticker or compare two or three

Compare

CRDF

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if bought

View Trends For CRDF
(Try 14 days for Free)

Ad is loading...

A.I.Advisor

published price charts

A.I. Advisor

published General Information

General Information

a cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors

Industry Biotechnology

Profile

Fundamentals

Details

Industry

N/A

Address

11055 Flintkote Avenue

Phone

+1 858 952-7570

Employees

Web

https://www.cardiffoncology.com